Much Ado About ASPS: The Rapidly Changing Treatment Paradigms of 2022.
Breelyn A WilkyAlessandra MaledduPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
A recent randomized phase 2 study of sunitinib or cediranib in alveolar soft part sarcoma established benchmark activity for commonly used tyrosine kinase inhibitors. The impact of TKIs, as well as immunotherapy, has redefined treatment paradigms and greatly improved outcomes for this historically dismal sarcoma.